share_log

Why Star Lake BioscienceZhaoqing Guangdong's (SHSE:600866) Earnings Are Better Than They Seem

Why Star Lake BioscienceZhaoqing Guangdong's (SHSE:600866) Earnings Are Better Than They Seem

爲什麼 Star Lake Bioscience廣東肇慶(SHSE: 600866)的收益比看起來要好
Simply Wall St ·  04/30 06:10

Star Lake Bioscience Co., Inc.Zhaoqing Guangdong (SHSE:600866) announced a healthy earnings result recently, and the market rewarded it with a strong uplift in the stock price. This reaction by the market reaction is understandable when looking at headline profits and we have found some further encouraging factors.

廣東肇慶星湖生物科學股份有限公司(SHSE: 600866)最近公佈了健康的收益業績,市場以股價的強勁上漲作爲回報。從總體利潤來看,市場反應的這種反應是可以理解的,我們發現了一些進一步的令人鼓舞的因素。

earnings-and-revenue-history
SHSE:600866 Earnings and Revenue History April 29th 2024
SHSE: 600866 2024 年 4 月 29 日的收益和收入歷史記錄

A Closer Look At Star Lake BioscienceZhaoqing Guangdong's Earnings

仔細看看廣東肇慶星湖生物科技的收益

Many investors haven't heard of the accrual ratio from cashflow, but it is actually a useful measure of how well a company's profit is backed up by free cash flow (FCF) during a given period. In plain english, this ratio subtracts FCF from net profit, and divides that number by the company's average operating assets over that period. This ratio tells us how much of a company's profit is not backed by free cashflow.

許多投資者尚未聽說過現金流的應計比率,但它實際上是衡量公司在給定時期內自由現金流(FCF)在多大程度上支持利潤的有用指標。簡而言之,該比率從淨利潤中減去FCF,然後將該數字除以該時期公司的平均運營資產。這個比率告訴我們,一家公司的利潤中有多少沒有自由現金流的支持。

As a result, a negative accrual ratio is a positive for the company, and a positive accrual ratio is a negative. While it's not a problem to have a positive accrual ratio, indicating a certain level of non-cash profits, a high accrual ratio is arguably a bad thing, because it indicates paper profits are not matched by cash flow. That's because some academic studies have suggested that high accruals ratios tend to lead to lower profit or less profit growth.

因此,負的應計比率對公司來說是正數,而正的應計比率是負數。儘管應計比率爲正(表明非現金利潤達到一定水平)不是問題,但高應計比率可以說是一件壞事,因爲它表明紙質利潤與現金流不匹配。那是因爲一些學術研究表明,高應計比率往往會導致利潤下降或利潤增長放緩。

Star Lake BioscienceZhaoqing Guangdong has an accrual ratio of -0.12 for the year to March 2024. That implies it has good cash conversion, and implies that its free cash flow solidly exceeded its profit last year. In fact, it had free cash flow of CN¥2.1b in the last year, which was a lot more than its statutory profit of CN¥808.9m. Star Lake BioscienceZhaoqing Guangdong's free cash flow improved over the last year, which is generally good to see. However, that's not all there is to consider. The accrual ratio is reflecting the impact of unusual items on statutory profit, at least in part.

截至2024年3月的一年中,廣東肇慶星湖生物科學的應計比率爲-0.12。這意味着它具有良好的現金轉化率,也意味着其去年的自由現金流穩步超過了利潤。實際上,它去年的自由現金流爲21億元人民幣,遠遠超過其8.089億元人民幣的法定利潤。廣東星湖生物科學肇慶的自由現金流比去年有所改善,總體來說還是不錯的。但是,這還不是要考慮的全部。應計比率至少部分反映了不尋常項目對法定利潤的影響。

Note: we always recommend investors check balance sheet strength. Click here to be taken to our balance sheet analysis of Star Lake BioscienceZhaoqing Guangdong.

注意:我們始終建議投資者檢查資產負債表的實力。點擊此處查看我們對廣東肇慶星湖生物科學的資產負債表分析。

How Do Unusual Items Influence Profit?

不尋常的物品如何影響利潤?

Star Lake BioscienceZhaoqing Guangdong's profit was reduced by unusual items worth CN¥140m in the last twelve months, and this helped it produce high cash conversion, as reflected by its unusual items. In a scenario where those unusual items included non-cash charges, we'd expect to see a strong accrual ratio, which is exactly what has happened in this case. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. If Star Lake BioscienceZhaoqing Guangdong doesn't see those unusual expenses repeat, then all else being equal we'd expect its profit to increase over the coming year.

在過去的十二個月中,廣東星湖生物科學因價值1.4億元人民幣的不尋常物品而減少了利潤,這幫助其產生了很高的現金轉化率,其不尋常的項目就反映了這一點。在這些不尋常的項目包括非現金費用的情況下,我們預計會看到強勁的應計比率,而這正是本案中發生的情況。看到不尋常的項目使公司利潤損失從來都不是一件好事,但從好的方面來看,情況可能遲早會好轉。我們調查了數千家上市公司,發現不尋常的物品本質上往往是一次性的。鑑於這些單列項目被認爲不尋常,這並不奇怪。如果廣東省肇慶星湖生物科技不出現這些不尋常的支出重演,那麼在其他條件相同的情況下,我們預計其利潤將在來年增加。

Our Take On Star Lake BioscienceZhaoqing Guangdong's Profit Performance

我們對廣東星湖生物科技肇慶盈利表現的看法

Considering both Star Lake BioscienceZhaoqing Guangdong's accrual ratio and its unusual items, we think its statutory earnings are unlikely to exaggerate the company's underlying earnings power. Looking at all these factors, we'd say that Star Lake BioscienceZhaoqing Guangdong's underlying earnings power is at least as good as the statutory numbers would make it seem. Keep in mind, when it comes to analysing a stock it's worth noting the risks involved. You'd be interested to know, that we found 2 warning signs for Star Lake BioscienceZhaoqing Guangdong and you'll want to know about these bad boys.

考慮到廣東星湖生物科學的應計比率及其不尋常的項目,我們認爲其法定收益不太可能誇大該公司的基礎盈利能力。從所有這些因素來看,我們可以說,廣東星湖生物科學肇慶的潛在盈利能力至少與法定數字所顯示的一樣好。請記住,在分析股票時,值得注意所涉及的風險。你可能會有興趣知道,我們發現了廣東星湖生物科學的兩個警示標誌,你會想知道這些壞孩子的情況。

After our examination into the nature of Star Lake BioscienceZhaoqing Guangdong's profit, we've come away optimistic for the company. But there is always more to discover if you are capable of focussing your mind on minutiae. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. While it might take a little research on your behalf, you may find this free collection of companies boasting high return on equity, or this list of stocks that insiders are buying to be useful.

在我們研究了廣東星湖生物科技有限公司利潤的性質之後,我們對該公司持樂觀態度。但是,如果你能夠將注意力集中在細節上,總會有更多的事情需要發現。例如,許多人認爲高股本回報率是有利的商業經濟的標誌,而另一些人則喜歡 “關注資金”,尋找內部人士正在買入的股票。雖然可能需要你進行一些研究,但你可能會發現這份免費收集的擁有高股本回報率的公司,或者這份內部人士正在購買的股票清單很有用。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論